Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
City University of New York, U.S.
Reports from the United States and Japan advance knowledge in vaccines research
July 4th, 2006
Reports from the United States and Japan highlight recent research in vaccines. Study 1: Topical imiquimod is a potent adjuvant to a weakly immunogenic protein prototype vaccine. According to recent research published in the journal Vaccine, "A major challenge in the development of more effective vaccines for cancer and other diseases is the development of potent adjuvants that can strongly, simply, and safely enhance vaccine immunogenicity. Adjuvants that preferentially enhance Th1 type of responses are particularly desirable, as these responses are believed to play the major role in immune resistance to cancer. This study describes the...
Source: Pharma Law Weekly (2006-07-04)
|
